{"Symbol": "ADAG", "AssetType": "Common Stock", "Name": "Adagene Inc", "Description": "Adagene Inc., a clinical-stage biopharmaceutical company, is dedicated to the research, development, and production of monoclonal antibody drugs for cancer. The company is headquartered in Suzhou, China.", "CIK": "1818838", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "HEALTHCARE", "Industry": "BIOTECHNOLOGY", "Address": "BUILDING C14, SUZHOU, CHINA, 215123", "OfficialSite": "https://www.adagene.com", "FiscalYearEnd": "December", "LatestQuarter": "2025-06-30", "MarketCapitalization": "84836000", "EBITDA": "-32765248", "PERatio": "None", "PEGRatio": "None", "BookValue": "0.804", "DividendPerShare": "None", "DividendYield": "None", "EPS": "-0.64", "RevenuePerShareTTM": "0.002", "ProfitMargin": "0", "OperatingMarginTTM": "-322.84", "ReturnOnAssetsTTM": "-0.249", "ReturnOnEquityTTM": "-0.633", "RevenueTTM": "103200", "GrossProfitTTM": "103200", "DilutedEPSTTM": "-0.64", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "-0.873", "AnalystTargetPrice": "9.51", "AnalystRatingStrongBuy": "0", "AnalystRatingBuy": "6", "AnalystRatingHold": "2", "AnalystRatingSell": "0", "AnalystRatingStrongSell": "0", "TrailingPE": "-", "ForwardPE": "-", "PriceToSalesRatioTTM": "1484.21", "PriceToBookRatio": "4.04", "EVToRevenue": "941.81", "EVToEBITDA": "1.121", "Beta": "0.728", "52WeekHigh": "3.26", "52WeekLow": "1.3", "50DayMovingAverage": "1.937", "200DayMovingAverage": "1.869", "SharesOutstanding": "47131300", "SharesFloat": "15915600", "PercentInsiders": "4.700", "PercentInstitutions": "31.619", "DividendDate": "None", "ExDividendDate": "None"}